biotina

Vitamin B7 (Biotin): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Synonyms

Biotin, also known as vitamin B7 or vitamin H, is a water-soluble vitamin that acts as an essential cofactor in many cellular metabolic processes, including fatty acid biosynthesis, fatty acid oxidation, amino acid metabolism, and gluconeogenesis. The compound has historically carried several names: by the 1940s, it was clear that all three compounds that were discovered and isolated separately — biotin, vitamin H, and coenzyme R — were identical. The designation "vitamin H" derives from the German words Haar und Haut (hair and skin), reflecting the early observations of dermatological deficiency signs.

The chemical name of biotin is hexahydro-2-oxo-1H-thieno(3,4-d)imidazole-4-pentanoic acid. Based on the degradation studies on biotin, its correct structural formula (C₁₀H₁₆N₂O₃S) was determined in the 1950s. In nature, the biotin molecule exists in the form of 8 stereoisomers, but only the D-biotin isomer is biologically active.

Natural Sources

Biotin is a relatively stable substance, widely distributed in nature, and is especially abundant in egg yolk, beef liver, and yeast. Biotin is found in many different foods, but its bioavailability varies greatly. Eggs provide a very rich source of biotin, but egg white contains a compound called avidin, which binds biotin and makes it unavailable for absorption. Thoroughly cooking eggs destroys avidin and allows the biotin in the yolk to be used. Other food sources of biotin include liver, milk, legumes, and nuts. Additional dietary sources include various meats such as pork, beef, and chicken, and certain types of fish such as salmon and tuna. Nuts and seeds — almonds, peanuts, walnuts, and sunflower seeds — are also good sources of biotin.

Humans cannot synthesize biotin and thus must obtain this vitamin from exogenous sources. The intestine is exposed to two sources of biotin: a dietary source and a bacterial source, which is the normal microflora of the large intestine. Bacteria resident in the large intestine may synthesize biotin that is absorbed and utilized by the host organism.

Common Forms and Preparations

Biotin is found in some multivitamin/mineral supplements, in B-complex supplements, and in supplements containing only biotin. It is commercially produced by chemical synthesis and is available in tablet, capsule, softgel, and liquid forms. In clinical research contexts, a high-dose pharmaceutical-grade formulation known as MD1003 has been studied at doses of 100 mg three times daily (300 mg/day total) for specific neurological indications.

2. Historical Discovery and Traditional Use

Scientific Discovery

By the 1920s, it became apparent that "water-soluble B" (vitamin B) was not a single substance. In particular, fresh yeast could prevent both beriberi and pellagra, but the "antipolyneuritis factor" in yeast is thermolabile, while the antipellagra factor is heat stable, suggesting that there are at least two water-soluble vitamins. Various terms were proposed for these water-soluble factors, but vitamins B(1) and B(2) were most widely used to refer to the thermolabile and heat-stable factors, respectively. Although vitamin B(1) proved to be a single chemical substance (thiamin), vitamin B(2) was ultimately found to be a complex of several chemically unrelated heat-stable factors, including niacin and biotin.

Biotin was originally called vitamin H, isolated in pure form in 1935, and its structure was established in 1942, after it had been shown to be required by animals. Evidence for the necessity of biotin appeared with the discovery in 1927 that the addition of uncooked egg white to a diet that is otherwise adequate produces toxicity and disease. This is because egg white contains a specific protein, avidin, that combines with biotin and thus prevents its absorption. In 1940, Esmond E. Snell, an American biochemist, found that a molecule called avidin binds biotin in an irreversible manner, thereby preventing its absorption and leading to egg-white injuries.

An invited biochemist (and later, a Nobel laureate), Vincent du Vigneaud, along with György and colleagues, proposed the structure of biotin in 1942. Stanton Harris and coworkers synthesized biotin in the subsequent year. Recognition that biotin and pantothenic acid are vitamins occurred somewhat later as a result of efforts to understand microbial growth factors. The metabolic roles in humans of these substances were ultimately elucidated by human experiments using particular toxins and by studies of rare inborn errors of metabolism. Symptomatic nutritional deficiencies of biotin and pantothenic acid were, and continue to be, rare.

Traditional and Historical Use

Unlike many botanical dietary supplements, biotin did not have a documented role in classical herbal or ethnobotanical traditions. Its status as an essential nutrient was established through 20th-century biochemistry rather than through pre-scientific medical traditions. The late 1940s and early 1950s had a series of publications on experimental studies that reflect the role of biotin in metabolic reactions. Prior to chemical isolation, biotin would have been consumed as part of varied diets rich in liver, eggs, yeast, and legumes — foods that feature prominently in diverse culinary traditions worldwide — but without any specific awareness of biotin as a constituent.

3. Key Constituents, Biochemistry, and Mechanisms of Action

Role as an Enzymatic Cofactor

Biotin is a cofactor for five carboxylases — propionyl-CoA carboxylase, pyruvate carboxylase, methylcrotonyl-CoA carboxylase (MCC), acetyl-CoA carboxylase 1, and acetyl-CoA carboxylase 2 — that catalyze critical steps in the metabolism of fatty acids, glucose, and amino acids. These five enzymes are collectively responsible for fundamental metabolic processes including gluconeogenesis, fatty acid synthesis, and branched-chain amino acid catabolism. Biotin-dependent carboxylases catalyze the fixation of bicarbonate in organic acids and play crucial roles in the metabolism of fatty acids, amino acids, and glucose. Carboxylase activities decrease substantially in response to biotin deficiency.

Mechanism of Carboxylase Activation

Biotin's chemical role is to enhance nucleophilicity. The carboxylation reactions occur in two separate steps. ATP is required for activation in the first step. Phosphorylation of bicarbonate by ATP to form carbonyl phosphate provides an electrophilic mixed-acid anhydride, which then reacts to generate reactive N(10)-carboxylbiotinyl enzyme. This in turn sets the stage for the transfer of the activated carboxylate function to an accepting substrate, typically at a carbon with carbanion character.

Gene Regulation and Histone Modification

Biotin also plays key roles in histone modifications, gene regulation (by modifying the activity of transcription factors), and cell signaling. Biotin is covalently attached to histones; biotinylated histones are enriched in repeat regions in the human genome and appear to play a role in transcriptional repression of genes and genome stability.

Absorption and Metabolism

Most biotin in foods is bound to protein, although some dietary biotin is in the free form. Gastrointestinal proteases and peptidases break down the protein-bound forms of ingested biotin into biocytin and biotin-oligopeptides, which undergo further processing by biotinidase, an enzyme, in the intestinal lumen to release free biotin. The free biotin is then absorbed in the small intestine, and most biotin is stored in the liver. Biotin uptake by human intestinal brush border membrane vesicles occurs via a carrier-mediated system that is Na⁺ gradient-dependent and capable of moving the substrate against a concentration gradient. Higher biotin transport is found in the proximal compared with the distal small intestine.

Biotin homeostasis in the human body is maintained by an effective mechanism cycle consisting of intestinal absorption, interaction with carboxylase and histones, and conversion to free biotin. Biotinidase (BTD), holocarboxylase synthase (HCS) enzymes, and sodium-dependent multivitamin transporter (SMVT) play important roles in biotin homeostasis.

4. Dietary Reference Intakes and Recommended Amounts

An RDA (Recommended Dietary Allowance) does not exist for biotin because there is not enough evidence to suggest a daily amount needed by most healthy people. Instead, there is an AI (Adequate Intake) level, which is assumed to ensure nutritional adequacy. The AI for biotin for men and women 19 years and older and for pregnant women is 30 micrograms daily. Lactating women need 35 micrograms daily.

The official US and Canadian recommendations for daily intake of biotin are as follows: for infants, newborn to five months, 5 mcg; six to eleven months, 6 mcg; for children, one to three years, 8 mcg; four to eight years, 12 mcg; and nine to thirteen years, 20 mcg; for teenagers, fourteen to eighteen years, 25 mcg; and for adults nineteen years and older, 30 mcg.

5. Scientific Evidence by Area of Use

5.1 Biotinidase Deficiency and Holocarboxylase Synthetase Deficiency

The most robustly established clinical application of biotin supplementation is in the management of inherited enzyme deficiencies. Biotinidase deficiency (BD) is an autosomal recessive disorder that originates by a deficiency of the biotinidase enzyme. The incidence of combined (partial and profound) and profound BD was reported as 1 per 60,089 and 1 per 112,271 live births, respectively. Biotinidase deficiency has a fundamental influence on neurocutaneous organs and as a cause of neurological disorders; however, it is indicated by symptoms that can be effectively treated or prevented with therapeutic doses of biotin.

In a clinical cohort study of five Malaysian patients with holocarboxylase synthetase (HLCS) deficiency, most patients (4/5) had late-onset presentations and responded well to biotin. Of the four who survived, biotin doses of 10–30 mg daily maintained metabolic stability. Most patients in this cohort had good outcomes from biotin supplementation, emphasizing the need for early intervention to prevent irreversible neurological damage. The evidence for treating these genetic enzyme deficiency conditions is well-established and strong.

5.2 Hair Loss and Nail Health

Biotin is perhaps most widely used — and most frequently marketed — for hair and nail conditions. The evidence base, however, is substantially weaker than popular perception suggests. A systematic review published in Skin Appendage Disorders (Patel et al., 2017, PMC5582478) found 18 reported cases of biotin use for hair and nail changes. In all cases, patients receiving biotin supplementation had an underlying pathology for poor hair or nail growth. All cases showed evidence of clinical improvement after receiving biotin.

However, the same review concluded that despite its popularity in the media and amongst consumers, biotin has no proven efficacy in hair and nail growth of healthy individuals. Only one study had shown decreased levels of biotin in healthy individuals, though this data was confounded by multiple factors, including patient history. Therefore, in the absence of additional studies, the authors found no evidence to suggest benefit from biotin supplementation outside of known deficiencies secondary to congenital or acquired causes.

Of the 18 cases reviewed, ten were reports of patients with inherited enzyme deficiency in either biotinidase or holocarboxylase synthetase. Of these 10, eight cases reported alopecia that subsequently resolved after varying months of biotin supplementation. Additionally, there were three reported cases of uncombable hair syndrome that all showed improvement in hair quality after a few months of biotin supplementation.

A more recent 2026 PRISMA-compliant systematic review (MDPI, CRD420251274919) reinforced these findings, noting that ten studies were included and that, across controlled and quasi-experimental interventions, biotin monotherapy did not show consistent benefit on objective hair outcomes. While overt biotin deficiency can be associated with hair changes, clinically meaningful deficiency is uncommon in individuals consuming a balanced diet, and published findings on biotin status in hair loss populations are inconsistent.

A comprehensive literature review by the Journal of the American Academy of Dermatology (JAAD, 2018) noted that of the 30 articles reviewed, 28 were case reports or case series with patients ranging in age from 2 months to 54 years. The overwhelming majority involved infants and children. Many diagnoses were nonspecific, listed as hair loss or alopecia. Follow-up ranged from weeks to 2 years, and improvement in hair conditions (alopecia, telogen effluvium, uncombable hair syndrome, etc.) was reported in 30 cases. However, it is difficult to determine whether conditions would have resolved with time regardless of supplementation. The same source noted that biotin dosing in the trials ranged from 2.5 to 20 mg/day.

Biotin has not been shown to be beneficial for normal, healthy hair or in individuals with no biotin deficiency. A distorted view of biotin as a wonder drug for hair growth prevails in modern culture, and there is little to no reason to believe that biotin supplementation should be recommended for individuals with healthy hair; its use should be limited to select, evidence-based clinical situations.

For nail conditions specifically, a PubMed review (PMID 29057689) found that clinical trials have shown an improvement in firmness, hardness, and thickness of brittle nails with oral biotin. There are some case reports and series demonstrating that oral biotin may improve triangular worn-down nails, trachyonychia, and habit tic nail deformity. The overall evidence for nail brittleness is preliminary and based on small trials and case series. Very few large-scale randomized controlled trials exist for biotin supplementation in dermatology. The lack of standardized dosing and standardized outcome measures makes comparison across existing studies challenging.

The NIH ODS states plainly that dietary supplements that contain biotin are often promoted to improve the health of hair, skin, and nails, but there is little scientific evidence to support these claims.

5.3 Blood Glucose Regulation and Type 2 Diabetes

Research has explored biotin's potential role in glycemic control. A 2022 systematic review and meta-analysis published in Frontiers in Nutrition (PMC9659605) searched PubMed, Embase, and Cochrane library databases and included five randomized controlled trials (RCTs) involving 445 participants. A total of five RCTs involving 445 participants were included. It was suggested that biotin supplementation for 28 to 90 days significantly decreased the level of fasting blood glucose (FBG) (MD: −1.21 mmol/L, 95% CI: −2.73 to 0.31), total cholesterol (TC) (MD: −0.22 mmol/L, 95% CI: −0.25 to −0.19) and triglycerides (TG) (MD: −0.59 mmol/L, 95% CI: −1.21 to 0.03). No significant beneficial effects were observed on insulin (MD: 1.88 pmol/L, 95% CI: −13.44 to 17.21). However, another biotin intervention lasting 4 weeks showed no significant change in plasma glucose, insulin, TG, TC, or lactate concentration compared with placebos.

Evidence for HbA1c was not enough because only one trial reported this parameter. Therefore, considering the small number of included studies, no conclusion can be made on the effects of biotin supplementation on insulin, HbA1c, LDL-C, HDL-C, and TG/HDL-C ratio. Overall, the glycemic evidence is preliminary and mixed, with confidence intervals for the primary endpoint of fasting blood glucose crossing zero, suggesting the benefit is not statistically robust. Larger, well-designed RCTs are needed before firm conclusions can be drawn.

In an earlier double-blind, placebo-controlled trial, the combination of chromium picolinate and biotin (CPB) had been shown to reduce insulin resistance and hyperglycemia in patients with type 2 diabetes. Thirty-six moderately obese subjects with T2DM and impaired glycemic control were randomized to receive CPB or placebo in addition to their oral hyperglycemic agents for 4 weeks. It is important to note that in this and related studies, biotin was used in combination with chromium picolinate, making it difficult to isolate the effect of biotin alone.

5.4 Progressive Multiple Sclerosis

One of the most extensively studied and debated applications of high-dose biotin in recent years has been in progressive multiple sclerosis (MS). The rationale centers on biotin's role in supporting oligodendrocyte energy metabolism and myelin synthesis.

An initial phase 2/3 randomized controlled trial (MS-SPI, Multiple Sclerosis, 2016, PMID 27589059) enrolled 154 patients with progressive MS (baseline EDSS 4.5–7). Patients were randomised to 12-month MD1003 (100 mg biotin three times daily) or placebo, followed by 12-month open-label MD1003 for all patients. The primary endpoint was disability reversal at month 9, confirmed at month 12, defined as an EDSS decrease of ≥1 point or a ≥20% decrease in timed 25-foot walk time. A total of 13 (12.6%) MD1003-treated patients achieved the primary endpoint versus none of the placebo-treated patients (p = 0.005). MD1003 treatment also reduced EDSS progression and improved clinical impression of change compared with placebo. Efficacy was maintained over follow-up, and the safety profile of MD1003 was similar to that of placebo.

However, the larger phase 3 SPI2 trial (Lancet Neurology, 2020, NCT02936037) enrolled 642 participants and produced a contradictory result. This study showed that MD1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1003 cannot be recommended for treatment of progressive multiple sclerosis.

A small pilot study had provided initial evidence that high doses of biotin might have an impact on disability and progression. A clinical trial in secondary and primary progressive MS ultimately failed to show that biotin leads to improvements in disability. No further clinical trials are planned. The evidence base for MD1003 in progressive MS is therefore currently negative at the highest level of evidence.

In a separate pilot trial in ALS, patients were assigned (2:1) to receive oral MD1003 (300 mg/day) or placebo for 24 weeks, and the safety profile of MD1003 in ALS was good, but the investigators did not find evidence of efficacy.

5.5 Pregnancy and Marginal Biotin Deficiency

The rapidly dividing cells of the developing fetus require biotin for synthesis of essential carboxylases and for histone biotinylation; hence, the maternal biotin requirement is likely increased during pregnancy. Research suggests that a substantial number of women develop marginal or subclinical biotin deficiency during normal pregnancy. Recent studies have shown marginal biotin deficiency can be present in human gestation, as evidenced by increased urinary excretion of 3-hydroxyisovaleric acid, decreased urinary excretion of biotin and bisnorbiotin, and decreased plasma concentration of biotin. There is some evidence that slight biotin deficiency may occur during normal pregnancy. For this reason, pregnant women are advised to take a prenatal vitamin that contains the recommended amount of biotin.

6. Body Systems and Health Areas Associated with Biotin

Metabolic and Energy Systems

Biotin plays a vital role in assisting enzymes to break down fats, carbohydrates, and proteins in food. It also helps to regulate signals sent by cells and the activity of genes. This foundational metabolic role makes biotin relevant to overall cellular energy homeostasis, macronutrient utilization, and metabolic health.

Integumentary System (Skin, Hair, and Nails)

Biotin deficiency can cause thinning hair and loss of body hair; a rash around the eyes, nose, mouth, and anal area; pinkeye; high levels of acid in the blood and urine; seizures; skin infection; brittle nails; and nervous system disorders. Biotin plays a crucial role in gene regulation, histone modifications, and cell functions. Due to its role in the production of keratin, a protein involved in the formation of nails, skin, and hair, it has become popularized as a supplement touted for beauty uses.

Nervous System

The clinical presentation of biotin deficiency involves abnormalities of the hair, skin, nails, and the central nervous system. Seizures, hypotonia, ataxia, optic atrophy, visual deficits, sensorineural deafness, and developmental delay (in children) are some of the neurologic manifestations. Biotin activates enzymes involved in cellular energy production and myelin synthesis, which underlies the rationale for its investigation in demyelinating neurological conditions. Symptoms of biotin deficiency in infants include weak muscle tone, sluggishness, and delayed development.

Endocrine and Metabolic System

Similar effects in type 1 diabetic patients showed FBG levels decreased up to 50% after daily administration of 16 mg biotin for one week. High-dose biotin may compensate for subnormal insulin exposure by suppressing FOXO1 levels. These mechanistic hypotheses — while biologically plausible — require confirmation in large, well-controlled clinical trials.

7. Deficiency: Causes, At-Risk Groups, and Symptoms

Causes of Deficiency

Although biotin deficiency is uncommon due to its presence in a wide range of foods and endogenous synthesis by intestinal microbiota, it should be considered in patients with identifiable risk factors. These include prolonged use of medications such as anticonvulsants or antibiotics and undernutrition.

Biotin deficiency may occur as a result of insufficient biotin intake through diet, drug-biotin interactions, increase in biotin degradation in pregnancy and smoking, decrease in the activities of BTD, SMVT, and HCS proteins, use of lipoic acid, anticonvulsants, long-term antibiotics, or short bowel syndrome.

Severe biotin deficiency has been seen in people who frequently eat large quantities of raw egg whites. Raw egg whites contain a protein that blocks the absorption of biotin. Cooked egg whites do not present this problem.

Drug Interactions Affecting Biotin Status

Anticonvulsant medications used to prevent seizures in individuals with epilepsy increase the risk of biotin depletion because anticonvulsants can interfere with the intestinal absorption and renal reabsorption of biotin and likely also increase degradation of biotin to inactive metabolites. Potential mechanisms of biotin depletion by the anticonvulsants primidone (Mysoline), phenytoin (Dilantin, Phenytek), and carbamazepine (Carbatrol, Epitol, Equetro, Tegretol) include inhibition of biotin intestinal absorption. Long-term treatment with antibacterial sulfonamide (sulfa) drugs or other antibiotics may decrease bacterial synthesis of biotin.

The incidence of biotin deficiency and suboptimal levels has been reported with increased frequency in patients on long-term parenteral nutrition, in patients with inborn errors of biotin metabolism, and in those on long-term therapy with anticonvulsant agents. Suboptimal levels of biotin have also been reported in a substantial number of alcoholics, in women during pregnancy, and in patients with inflammatory bowel disease.

8. Dosage Forms and Doses Reported in Studies

The following dosages are drawn directly from studies and authoritative sources; they are not recommendations.

• Adequate Intake (AI), adults 19+ years: 30 micrograms (mcg) daily for men and women 19 years and older and for pregnant women.
• AI, lactating women: 35 micrograms daily.
• Biotinidase/holocarboxylase synthetase deficiency (clinical): Biotin doses of 10–30 mg daily maintained metabolic stability in a cohort of five patients studied.
• Hair and nail conditions (case reports and trials): Biotin dosing in the reviewed trials ranged from 2.5 to 20 mg/day.
• Brittle nails (clinical use): A dosage of 3,000 mcg daily has been used to treat brittle fingernails and toenails in reported studies.
• Diabetes (reported studies): Biotin supplementation interventions of 28 to 90 days duration were used in the five RCTs included in the 2022 meta-analysis.
• Progressive multiple sclerosis (MD1003 phase 2/3 trial): 100 mg biotin three times daily (300 mg/day total) was administered for 12 months.
• High-dose supplementation (safety data): Several studies have found no adverse effects of 10–50 mg/day biotin, and up to 200 mg/day oral biotin or 20 mg/day intravenously in patients with biotinidase deficiency do not produce symptoms of toxicity.
• Supplements marketed for hair, skin, and nails: Supplements marketed for hair, skin, and nails can contain up to 20 mg of biotin, which is more than 650 times the recommended allowance.

9. Safety Considerations and Interactions

General Toxicity Profile

The Food and Nutrition Board (FNB) was unable to establish tolerable upper intake levels (ULs) for biotin because there is no evidence in humans that biotin is toxic at high intakes. There is no established upper limit or toxic level for biotin.

Laboratory Test Interference — A Documented Clinical Hazard

The most clinically significant and well-documented safety concern with biotin supplementation is its interference with a broad range of clinical laboratory immunoassays. This is not a theoretical risk — it has been the subject of formal FDA safety communications.

The FDA issued an updated safety communication warning that biotin may interfere with lab tests, discussing concerns with biotin interference in certain laboratory tests and providing recommendations for consumers, health care providers, lab personnel, and lab test manufacturers. The FDA has continued to receive adverse event reports indicating biotin interference has caused falsely low troponin results. The FDA has received one report of a patient death resulting from an incorrect cardiac troponin assessment that occurred because of biotin interference.

Biotin levels higher than those observed with normal dietary intake of biotin-rich foods can interfere with troponin, human chorionic gonadotropin, thyroid-stimulating hormone, and other laboratory results. Reported instances of interference include assays for free thyroxine (T4), total T4, free triiodothyronine (T3), total T3, thyroid stimulating hormone (TSH), parathyroid hormone (PTH), testosterone, estradiol, β-human chorionic gonadotropin (β-hCG), ferritin, troponin, and various cancer markers.

The problem occurs because many immunoassays rely on biotin-streptavidin binding to capture antibodies. For example, biotin is used in immunoassay tests for cardiac troponins and thyroid stimulating hormone. Both false positive (FT4 and FT3) and false negative (TSH) thyroid studies have occurred due to elevated biotin levels. Another important example is hCG pregnancy testing; biotin can lead to false negative hCG results for both blood and urine pregnancy tests.

High biotin intakes, and potentially even intakes greater than the AI, may pose this type of health risk. Supplementing with biotin beyond recommended intakes can cause clinically significant falsely high or falsely low laboratory test results, depending on the test. These incorrect results may lead to inappropriate patient management or misdiagnosis of a medical condition.

Regarding timing of blood collection, based on studies showing how quickly biotin is cleared from the blood, people who have consumed 5,000–10,000 mcg biotin need to wait a minimum of 8 hours after the last dose before having blood collected for laboratory tests. Waiting up to 72 hours may be required to prevent interference with some immunoassays. Since biotin is cleared from the blood by the kidneys, people with kidney dysfunction or kidney disease may need to refrain from taking biotin for a longer period.

Anticonvulsant Drug Interactions

The biotin transport event across the human intestinal brush border membrane was sensitive to the inhibitory effect of the anticonvulsant drugs carbamazepine and primidone. Supplemental biotin has been suggested for patients who are treated with anticonvulsants that have been linked to biotin deficiency.

Avidin Interaction (Raw Egg Whites)

Those who frequently enjoy raw eggs in recipes for mayonnaise, Caesar dressing, or eggnog may want to reconsider. A protein in raw eggs called avidin can bind to biotin, preventing its absorption. Cooked eggs are not an issue because avidin is broken down when heated.

Potential Concern in Multiple Sclerosis Relapse

In the MS-SPI optic neuritis sub-study, the incidence of MS relapse was higher in the MD1003 group (9 of 65 patients; 13.8%) than in the placebo group (1 of 28 patients; 3.6%) during the double-blind phase of the study. This signal has been reported in other studies but has not been conclusively mechanistically explained, and the phase 3 SPI2 trial's null findings reduce the overall clinical relevance of this observation.

Hypoglycemia Risk in Diabetic Patients on Insulin

In clinical studies using MD1003 in multiple sclerosis, one patient with Type 1 diabetes who was receiving insulin experienced episodes of hypoglycemia approximately one year after initiating MD1003. These ceased when MD1003 was stopped and recurred on re-challenge.

10. Summary of Evidence Strength

• Biotinidase and holocarboxylase synthetase deficiency: Strong — well-established clinical indication with consistent treatment response across multiple case series and clinical follow-up studies.
• Laboratory test interference: Strong — validated across multiple assay platforms; supported by FDA safety communications and clinical case reports including a fatality.
• Hair and nail conditions in deficiency: Moderate — consistent clinical improvement documented in case reports, but evidence base is limited to case reports and small uncontrolled series; no benefit demonstrated in individuals without underlying deficiency or pathology.
• Hair and nail conditions in healthy individuals: Weak/Absent — no proven efficacy; the NIH ODS, multiple systematic reviews, and JAAD literature all consistently reach the same conclusion.
• Type 2 diabetes and glycemic control: Preliminary/Mixed — a meta-analysis of five RCTs suggests trends toward fasting glucose reduction, but confidence intervals cross zero and effect on HbA1c is underpowered; larger trials are needed.
• Progressive multiple sclerosis (MD1003): Negative at phase 3 level — an initial positive phase 2/3 trial was not replicated in a larger phase 3 trial; MD1003 is not currently recommended for this indication.
• Pregnancy-related marginal deficiency: Moderate evidence of subclinical biotin depletion during pregnancy; clinical significance of supplementation beyond standard prenatal AI levels remains unestablished.

References

• NIH Office of Dietary Supplements — Biotin: Fact Sheet for Health Professionals
• NIH Office of Dietary Supplements — Biotin: Fact Sheet for Consumers
• Harvard T.H. Chan School of Public Health, The Nutrition Source — Biotin (Vitamin B7)
• Patel DP, Swink SM, Castelo-Soccio L. A Review of the Use of Biotin for Hair Loss. Skin Appendage Disorders. 2017;3(3):166–169. PMC5582478
• Mock DM. Biotin and biotinidase deficiency. Expert Review of Endocrinology & Metabolism. 2009. PMC2726758
• Huang H et al. Influence of biotin intervention on glycemic control and lipid profile in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Frontiers in Nutrition. 2022. PMC9659605
• Tourbah A et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Multiple Sclerosis Journal. 2016. PMC5098693
• Cree BAC et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology. 2020. PMID 33222767
• U.S. Food & Drug Administration — Biotin Interference with Troponin Lab Tests
• Rosner I et al. Clinically Significant Lab Errors due to Vitamin B7 (Biotin) Supplementation: A Case Report Following a Recent FDA Warning. Cureus. 2019. PMC6802814
• Carpenter KJ. The discovery of niacin, biotin, and pantothenic acid. Annals of Nutrition and Metabolism. 2012. PMID 23183297
• Banerjee M et al. Biotin: DNA to diet. Journal of Nutritional Biochemistry. 2025. ScienceDirect
• Linus Pauling Institute, Oregon State University Micronutrient Information Center — Biotin
• Said HM. Cell and Molecular Aspects of Human Intestinal Biotin Absorption. Journal of Nutrition. 2009. PMC2646215
• Saleem F, Soos MP. Biotin Deficiency. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. NBK547751
• Lipner SR. Biotin for the treatment of nail disease: what is the evidence? Journal of Dermatological Treatment. 2018. PMID 29057689
• Systematic Review: Effectiveness of Biotin Supplementation for Hair Growth in Patients with Alopecia. Dermatology Reports. 2026.
• Meininger V et al. High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study. PLOS ONE. 2020. PMC7046518
• Walth CB et al. Response to: "Rethinking biotin therapy for hair, nail, and skin disorders." Journal of the American Academy of Dermatology. 2018.
• Medscape — Biotin Deficiency: Practice Essentials, Background, Pathophysiology